Balancing the Risks of Restenosis and Stent Thrombosis in Bare-Metal Versus Drug-Eluting Stents: Results of a Decision Analytic Model
- 13 May 2008
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 51 (19), 1844-1853
- https://doi.org/10.1016/j.jacc.2008.01.042
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Twenty-Five–Year Trends in In-Hospital and Long-Term Outcome After Percutaneous Coronary InterventionCirculation, 2007
- Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting StentsNew England Journal of Medicine, 2007
- Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting StentsJournal of the American College of Cardiology, 2006
- Bare metal stent restenosis is not a benign clinical entityAmerican Heart Journal, 2006
- Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting StentsCirculation, 2006
- Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting StentsJAMA, 2005
- Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantationJournal of the American College of Cardiology, 2005
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Stent Thrombosis in the Modern EraCirculation, 2001